Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial. . BMJ 2025;391:r2300.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial. BMJ 2025;391:r2300.
PMID: 41184034